These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27660467)

  • 1. Sunitinib: the antiangiogenic effects and beyond.
    Hao Z; Sadek I
    Onco Targets Ther; 2016; 9():5495-505. PubMed ID: 27660467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
    Papaetis GS; Syrigos KN
    BioDrugs; 2009; 23(6):377-89. PubMed ID: 19894779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report.
    Sbitti Y; Debbagh A; Slimani K; Mahi M; Errihani H; Ichou M
    J Med Case Rep; 2018 Mar; 12(1):80. PubMed ID: 29554941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
    Ayllon J; Beuselinck B; Morel A; Barrascout E; Medioni J; Scotte F; Oudard S
    Cancer Invest; 2011 May; 29(4):282-5. PubMed ID: 21469976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib: from rational design to clinical efficacy.
    Chow LQ; Eckhardt SG
    J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.
    Christensen JG
    Ann Oncol; 2007 Sep; 18 Suppl 10():x3-10. PubMed ID: 17761721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
    Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
    Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.
    Yeramian A; Sorolla A; Velasco A; Santacana M; Dolcet X; Valls J; Abal L; Moreno S; Egido R; Casanova JM; Puig S; Vilella R; Llombart-Cussac A; Matias-Guiu X; Martí RM
    Int J Cancer; 2012 Feb; 130(4):967-78. PubMed ID: 21445974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab.
    Walraven M; Homs MYV; van der Veldt AAM; Dekker H; Koldenhof J; Honeywell R; Barendrecht A; Sebastian SAE; Parr N; Koekman AC; Voest EE; Roest M; Korporaal SJA; Verheul HMW
    Angiogenesis; 2018 May; 21(2):325-334. PubMed ID: 29532289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
    de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS
    Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor.
    George S
    Curr Oncol Rep; 2007 Jul; 9(4):323-7. PubMed ID: 17588358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
    Hiles JJ; Kolesar JM
    Am J Health Syst Pharm; 2008 Jan; 65(2):123-31. PubMed ID: 18192256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
    Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
    Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.
    Nilsson MB; Zage PE; Zeng L; Xu L; Cascone T; Wu HK; Saigal B; Zweidler-McKay PA; Heymach JV
    Oncogene; 2010 May; 29(20):2938-49. PubMed ID: 20208561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
    Wu CL; Ping SY; Yu CP; Yu DS
    Kaohsiung J Med Sci; 2012 Apr; 28(4):194-203. PubMed ID: 22453067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
    Pilskog M; Bostad L; Edelmann RJ; Akslen LA; Beisland C; Straume O
    J Pathol Clin Res; 2018 Apr; 4(2):114-123. PubMed ID: 29665322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternate sunitinib schedules in patients with metastatic renal cell carcinoma.
    Kalra S; Rini BI; Jonasch E
    Ann Oncol; 2015 Jul; 26(7):1300-4. PubMed ID: 25628443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.